Cargando…

Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer

Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Østrup, Olga, Nysom, Karsten, Scheie, David, Schmidt, Ane Y., Mathiasen, Rene, Hjalgrim, Lisa L., Olsen, Tina E., Skjøth-Rasmussen, Jane, Henriksen, Birthe M., Nielsen, Finn C., Wehner, Peder S., Schrøder, Henrik, Sehested, Astrid M., Rechnitzer, Catherine, Rossing, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920151/
https://www.ncbi.nlm.nih.gov/pubmed/29732366
http://dx.doi.org/10.3389/fped.2018.00114
_version_ 1783317777928421376
author Østrup, Olga
Nysom, Karsten
Scheie, David
Schmidt, Ane Y.
Mathiasen, Rene
Hjalgrim, Lisa L.
Olsen, Tina E.
Skjøth-Rasmussen, Jane
Henriksen, Birthe M.
Nielsen, Finn C.
Wehner, Peder S.
Schrøder, Henrik
Sehested, Astrid M.
Rechnitzer, Catherine
Rossing, Maria
author_facet Østrup, Olga
Nysom, Karsten
Scheie, David
Schmidt, Ane Y.
Mathiasen, Rene
Hjalgrim, Lisa L.
Olsen, Tina E.
Skjøth-Rasmussen, Jane
Henriksen, Birthe M.
Nielsen, Finn C.
Wehner, Peder S.
Schrøder, Henrik
Sehested, Astrid M.
Rechnitzer, Catherine
Rossing, Maria
author_sort Østrup, Olga
collection PubMed
description Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of extensive molecular profiling by assessing the frequency of identified biological onco-drivers, altered diagnosis, and/or identification of new relevant targeted therapies. Patients and Methods: Forty-six tumor samples (44 fresh-frozen; two formalin-fixed paraffin embedded), two bone marrow aspirates, three cerebrospinal fluid samples, and one archived DNA were obtained from 48 children (0–17 years; median 9.5) with relapsed or refractory cancer, where the disease was rapidly progressing in spite of their current treatment or they had exhausted all treatment options. The samples were analyzed by whole-exome sequencing (WES), RNA sequencing (RNAseq), transcriptome arrays, and SNP arrays. Final reports were available within 3–4 weeks after patient inclusion and included mutation status, a description of copy number alterations, differentially expressed genes, and gene fusions, as well as suggestions for targeted treatment. Results: Of the 48 patients, 33 had actionable findings. The most efficient method for the identification of actionable findings was WES (39%), followed by SNP array (37%). Of note, gene fusions were identified by RNAseq in 21% of the samples. Eleven findings led to clinical intervention, i.e., oncogenetic counseling, targeted treatment, and treatment based on changed diagnosis. Four patients received compassionate use targeted therapy. Six patients experienced direct benefits in the form of stable disease or response. Conclusion: The application of comprehensive genetic diagnostics in children with recurrent cancers allowed for discovery and implementation of effective targeted therapies and hereby improvement of outcome in some patients.
format Online
Article
Text
id pubmed-5920151
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59201512018-05-04 Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer Østrup, Olga Nysom, Karsten Scheie, David Schmidt, Ane Y. Mathiasen, Rene Hjalgrim, Lisa L. Olsen, Tina E. Skjøth-Rasmussen, Jane Henriksen, Birthe M. Nielsen, Finn C. Wehner, Peder S. Schrøder, Henrik Sehested, Astrid M. Rechnitzer, Catherine Rossing, Maria Front Pediatr Pediatrics Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of extensive molecular profiling by assessing the frequency of identified biological onco-drivers, altered diagnosis, and/or identification of new relevant targeted therapies. Patients and Methods: Forty-six tumor samples (44 fresh-frozen; two formalin-fixed paraffin embedded), two bone marrow aspirates, three cerebrospinal fluid samples, and one archived DNA were obtained from 48 children (0–17 years; median 9.5) with relapsed or refractory cancer, where the disease was rapidly progressing in spite of their current treatment or they had exhausted all treatment options. The samples were analyzed by whole-exome sequencing (WES), RNA sequencing (RNAseq), transcriptome arrays, and SNP arrays. Final reports were available within 3–4 weeks after patient inclusion and included mutation status, a description of copy number alterations, differentially expressed genes, and gene fusions, as well as suggestions for targeted treatment. Results: Of the 48 patients, 33 had actionable findings. The most efficient method for the identification of actionable findings was WES (39%), followed by SNP array (37%). Of note, gene fusions were identified by RNAseq in 21% of the samples. Eleven findings led to clinical intervention, i.e., oncogenetic counseling, targeted treatment, and treatment based on changed diagnosis. Four patients received compassionate use targeted therapy. Six patients experienced direct benefits in the form of stable disease or response. Conclusion: The application of comprehensive genetic diagnostics in children with recurrent cancers allowed for discovery and implementation of effective targeted therapies and hereby improvement of outcome in some patients. Frontiers Media S.A. 2018-04-20 /pmc/articles/PMC5920151/ /pubmed/29732366 http://dx.doi.org/10.3389/fped.2018.00114 Text en Copyright © 2018 Østrup, Nysom, Scheie, Schmidt, Mathiasen, Hjalgrim, Olsen, Skjøth-Rasmussen, Henriksen, Nielsen, Wehner, Schrøder, Sehested, Rechnitzer and Rossing. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Østrup, Olga
Nysom, Karsten
Scheie, David
Schmidt, Ane Y.
Mathiasen, Rene
Hjalgrim, Lisa L.
Olsen, Tina E.
Skjøth-Rasmussen, Jane
Henriksen, Birthe M.
Nielsen, Finn C.
Wehner, Peder S.
Schrøder, Henrik
Sehested, Astrid M.
Rechnitzer, Catherine
Rossing, Maria
Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title_full Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title_fullStr Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title_full_unstemmed Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title_short Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
title_sort importance of comprehensive molecular profiling for clinical outcome in children with recurrent cancer
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920151/
https://www.ncbi.nlm.nih.gov/pubmed/29732366
http://dx.doi.org/10.3389/fped.2018.00114
work_keys_str_mv AT østrupolga importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT nysomkarsten importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT scheiedavid importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT schmidtaney importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT mathiasenrene importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT hjalgrimlisal importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT olsentinae importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT skjøthrasmussenjane importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT henriksenbirthem importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT nielsenfinnc importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT wehnerpeders importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT schrøderhenrik importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT sehestedastridm importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT rechnitzercatherine importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer
AT rossingmaria importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer